{"entity":{"id":"nct06509906","kind":"trial","name":"M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is terminated.","summary":"The registry lists NCT06509906 as terminated, last updated 2025-12-18. Enrolment is 3 actual participants. Interventions: M9466, Irinotecan, Folinic acid, Fluorouracil (5-FU), Bevacizumab, Granulocyte colony stimulating factor (G-CSF). Primary measures include Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related TEAEs; Number of Participants with Dose Limiting Toxicity (DLT). The registry reason for stopping is: Sponsor Decision No results are posted in the registry; this does not exclude separate publications.","status":"withdrawn","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06509906","url":"https://clinicaltrials.gov/study/NCT06509906"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":["hrs-1167"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06509906","phase":"1","setting":"An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination With Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)","sponsor":"EMD Serono Research & Development Institute, Inc.","started":"2024-10-08","startedType":"actual","enrolled":3,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06509906/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"hrs-1167","kind":"drug","name":"HRS-1167","route":"/drugs/hrs-1167/"}]}}